Home / Companies / Substipharm
Company family
Substipharm: medicine shortages
As of 2 Nov 2026, 11 Substipharm products have a reported shortage across 6 countries, covering 6 medicines.
Products short11rank #165 of 464
Medicines6active ingredients
Countries6/16
New in 90 days20 vs market pace
Typical duration11 monthsmedian so far
Manufacturing22%demand-driven 11%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Droperidol | 3 | 31 Mar 2025 | Not stated | 4/16 | |
| Mitomycin | 3 | 18 Nov 2025 | Other | 7/16 | |
| Prasugrel | 2 | 22 Jan 2025 | Commercial decision or withdrawal | 4/16 | |
| Acetylsalicylic Acid | 1 | 9 Oct 2026 | Increased demand | 7/16 | |
| Calcium Folinate | 1 | 15 Jul 2026 | Manufacturing problem | 7/16 | |
| Polystyrene Sulfonate | 1 | 22 Sep 2025 | Manufacturing problem | 3/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.